These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37503185)

  • 1. Naltrexone blocks alcohol-induced effects on kappa-opioid receptors in the plasma membrane.
    Terenius L; Oasa S; Sezgin E; Ma Y; Horne D; Radmiković M; Jovanović-Talisman T; Martin-Fardon R; Vukojevic V
    Res Sq; 2023 Jul; ():. PubMed ID: 37503185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
    Zhou Y; Kreek MJ
    Brain Res; 2019 Dec; 1724():146410. PubMed ID: 31469985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-nociception mediated by a κ opioid receptor agonist is blocked by a δ receptor agonist.
    Taylor AM; Roberts KW; Pradhan AA; Akbari HA; Walwyn W; Lutfy K; Carroll FI; Cahill CM; Evans CJ
    Br J Pharmacol; 2015 Jan; 172(2):691-703. PubMed ID: 24923251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.
    Blum K; Modestino EJ; Badgaiyan RD; Baron D; Thanos PK; Elman I; Siwicki D; Febo M; Gold MS
    EC Psychol Psychiatr; 2018 Aug; 7(8):564-579. PubMed ID: 30417173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
    Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
    Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
    Zhou Y; Kreek MJ
    Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid Receptors in Immune and Glial Cells-Implications for Pain Control.
    Machelska H; Celik MÖ
    Front Immunol; 2020; 11():300. PubMed ID: 32194554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors.
    Zagon IS; McLaughlin PJ
    Brain Res; 1989 Feb; 480(1-2):16-28. PubMed ID: 2540873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
    Tzschentke TM; Rutten K
    Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors.
    Wang PC; Ho IK; Lee CW
    J Cell Mol Med; 2015 Nov; 19(11):2587-96. PubMed ID: 26153065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the molecular basis of the kappa opioid receptor selectivity: A Molecular Dynamics study.
    Saleh AH; Abdelwaly A; Darwish KM; Eissa AAHM; Chittiboyina A; Helal MA
    J Mol Graph Model; 2021 Jul; 106():107940. PubMed ID: 34015577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).
    DiMattio KM; Chen C; Shi L; Liu-Chen LY
    Eur J Pharmacol; 2015 Feb; 748():93-100. PubMed ID: 25481857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.
    Zhou Y; Crowley R; Prisinzano T; Kreek MJ
    Neurosci Lett; 2018 Apr; 673():19-23. PubMed ID: 29496608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?
    Bailey SJ; Husbands SM
    Neuronal Signal; 2018 Jun; 2(2):NS20170145. PubMed ID: 32714584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands.
    Pasquinucci L; Iadanza M; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Parenti C; De Luca L; Ronsisvalle G
    Pharmazie; 2007 Nov; 62(11):813-24. PubMed ID: 18065096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
    Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
    Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone alters the processing of social and emotional stimuli in healthy adults.
    Wardle MC; Bershad AK; de Wit H
    Soc Neurosci; 2016 Dec; 11(6):579-91. PubMed ID: 26710657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2000; (3):CD001867. PubMed ID: 10908513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001867. PubMed ID: 15674887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.